1357302-64-7

1357302-64-7 structure

Name: OG-L002
Chemical Name: [1,1'-Biphenyl]-3-ol, 4'-[(1R,2S)-2-aminocyclopropyl]-
CAS Number: 1357302-64-7
Molecular Formula: C₁₅H₁₅NO
Molecular Weight: 225.286
Catalog: Biochemical Inhibitor Epigenetics Histone Demethylase Inhibitor
Create Date: 2018-12-25 15:15:05
Modify Date: 2025-09-03 17:23:02
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC50 of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC50s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IEgenes[1].

Name	[1,1'-Biphenyl]-3-ol, 4'-[(1R,2S)-2-aminocyclopropyl]-
Synonyms	4'-[(1R,2S)-2-Aminocyclopropyl]-3-biphenylol [1,1'-Biphenyl]-3-ol, 4'-[(1R,2S)-2-aminocyclopropyl]- 4'-((1R,2S)-2-Aminocyclopropyl)biphenyl-3-ol OG-L002

Description	OG-L002 is a potent and highly selective LSD1 inhibitor with an IC50 of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC50s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IEgenes[1].
Related Catalog	Signaling Pathways >> Anti-infection >> HSV Research Areas >> Infection Signaling Pathways >> Epigenetics >> Histone Demethylase Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase
Target	IC50: 0.02 μM (LSD1), 1.38 μM (MAO-A), 0.72 μM (MAO-B), HSV IE[1]
In Vitro	OG-L002 inhibits viral IE gene expression in both cells with a significantly reduced IC50 (IC50: ~10 µM in HeLa cells; IC50: ~3 µM in HFF cells) relative to the control MAOI TCP (IC50: ~1 mM)[1].
In Vivo	OG-L002 (i.p.; 6-40 mg/kg; daily; for 7 days) reduces the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection[1]. Animal Model: 4-week-old BALB/c female mice[1] Dosage: 6, 20, 40 mg/kg Administration: Intraperitoneal; daily; for 7 days Result: Reduced the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection.
References	[1]. Liang Y, et al. A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. mBio. 2013 Feb 5;4(1):e00558-12.